PARACOCCIDIOIDOMYCOSIS: CHALLENGES IN THE DEVELOPMENT OF A VACCINE AGAINST AN ENDEMIC MYCOSIS IN THE AMERICAS

Paracoccidioidomycosis (PCM), caused by Paracoccidioides spp, is an important endemic mycosis in Latin America. There are two recognized Paracoccidioides species, P. brasiliensis and P. lutzii, based on phylogenetic differences; however, the pathogenesis and disease manifestations of both are indist...

Full description

Saved in:
Bibliographic Details
Published inRevista do Instituto de Medicina Tropical de São Paulo Vol. 57 Suppl 19; no. suppl 19; pp. 21 - 24
Main Authors Taborda, Carlos P, Urán, M E, Nosanchuk, J D, Travassos, L R
Format Journal Article
LanguageEnglish
Portuguese
Published Brazil Instituto de Medicina Tropical de Sao Paulo 01.09.2015
Instituto de Medicina Tropical
Universidade de São Paulo (USP)
Subjects
Animals
Antigens, Fungal - immunology
Antigens, Neoplasm - immunology
Fungal Vaccines - immunology
Glycoproteins - immunology
Humans
Immunoprotection
Mice
Paracoccidioides - immunology
Paracoccidioides brasiliensis
Paracoccidioides lutzii
Paracoccidioidomycosis - immunology
Paracoccidioidomycosis - therapy
Peptide Fragments - immunology
Peptide P10
TROPICAL MEDICINE
Vaccine
Vaccines, DNA - immunology
Immunoprotection
Vaccine
Paracoccidioides lutzii
Peptide P10
Paracoccidioides brasiliensis
Online AccessGet full text

Cover

More Information
Summary:Paracoccidioidomycosis (PCM), caused by Paracoccidioides spp, is an important endemic mycosis in Latin America. There are two recognized Paracoccidioides species, P. brasiliensis and P. lutzii, based on phylogenetic differences; however, the pathogenesis and disease manifestations of both are indistinguishable at present. Approximately 1,853 (~51,2%) of 3,583 confirmed deaths in Brazil due to systemic mycoses from 1996-2006 were caused by PCM. Antifungal treatment is required for patients with PCM. The initial treatment lasts from two to six months and sulfa derivatives, amphotericin B, azoles and terbinafine are used in clinical practice; however, despite prolonged therapy, relapses are still a problem. An effective Th1-biased cellular immune response is essential to control the disease, which can be induced by exogenous antigens or modulated by prophylactic or therapeutic vaccines. Stimulation of B cells or passive transference of monoclonal antibodies are also important means that may be used to improve the efficacy of paracoccidioidomycosis treatment in the future. This review critically details major challenges facing the development of a vaccine to combat PCM.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0036-4665
1678-9946
1678-9946
0036-4665
DOI:10.1590/S0036-46652015000700005